TrialFrontiers in immunology2025

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma.

Kunyuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.